Different treatment regimens based on current knowledge about ACTH rhythms were evaluated f o r controlling CAH. ~i r c h o r a l patt e r n s of plasma progestins (progesterone [ P I ,) and androgens (androstenedione, t e s t o s t e r o n e , dehydroepiandrosterone-S04)were analyzed.
Different treatment regimens based on current knowledge about ACTH rhythms were evaluated f o r controlling CAH. ~i r c h o r a l patt e r n s of plasma progestins (progesterone [ P I , ) and androgens (androstenedione, t e s t o s t e r o n e , dehydroepiandrosterone-S04)were analyzed.
Spacing cortisone (E) o r c o r t i s o l ( F ) i n 3 equal doses about q 8 h was found t o bring plasma androgen l e v e l s t o o r below normal in t h e 4 cases studied. Progestins were not so well cont r o l l e d , even by E doses large enough t o cause evidence o f o v e rdosage in 1 p a t i e n t . This treatment regimen was associated with a phase-shift of maximum adrenal secretion t o 0700-1120 hr. Therefore, two other replacement protocols were attempted in two cases: giving 40% of t h e d a i l y E or F dose upon a r i s i n g and/or a t bedtime. Both regimens were biochemically very inadequate. One p a t i e n t could not be controlled u n t i l a subc l i n i c a l Na-losing s t a t e was controlled by Florinef. Long-acting glucocorticoid (dexamethasoneidex) administration in one o r two, 101i.clnily doses proved t o be t h e only form of treatment which could normalize plasma 17P in two girls. With normalization of progestins, menses began o r resumed in t h e s e cases.
W e conclude: 1) control of progestin l e v e l s , p a r t i c u l a r l y 17P, i s impossible on standard forms of therapy in some cases of CAH. 2) t h i s i s occasionally due t o occult mineralocorticoid d e f iciency. 3) low-dose dex i s t h e best a v a i l a b l e therapy f o r some cases, and 4) elevation of progestins may be more important than t h a t of androgens in t h e oligomenorrhea of CAH. .2 Tha d a t a a r e within t h e normal range f o r s t a g e of maturation. !dhen expressed on an age-related basis, however, t h e d a t a r e f l e c t t h e delayed sexual development of these p a t i e n t s . Between 10 and 20 yr, l e v e l s of t h e adrenal androgen, DHAS, were s i g n i f i c a n t l y (fl.01) lower than in normal children. 23 CF p a t i e n t s underwent a 3 h r infusion of 100 Ug synthetic LHRH (f f SM):
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Carlos . I . Bourdony. Temple Univ. Sch. of Med., Dept. of Ped., S t . Christopher's Hospital f o r Children. Philadelphia Although hGH has been shown t o suppress the r e l e a s e of TSH, its a c t i o n on the metabolism of thyroid hormones remains unknown. W e examined the e f f e c t of hQl on a loading dose of T3 i n 11 hypop i t u i t a r y children (3 t o 18 years). Six p a t i e n t s were on o r a l Lthyroxine because of TSH deficiency. Before and a f t e r one month of hGH therapy (2U three times weekly), a s i n g l e dose of T j (50 t o 100 ug) was administered o r a l l y ; serum l e v e l s of T j and T4 were measured a t 0.4,6,12,18 and 24 hours. Both before and a f t e r hGH therapy. serum l e v e l s of T j peaked a t 4 hours and returned to normal by 24 hours. After hGH therapy, s i g n i f i c a n t l y higher l e v e l s of T3 were achieved a t 0.4.6.18 and 24 hours (p values from 0.003 t o 0.03). I n c o n t r a s t . following T j ingestion, serum l e v e l s of T4 decreased and reached a nadir a t 18 hours. The decrease i n serum l e v e l s of Ti, were of s i m i l a r magnitude whether the p a t i e n t s were o r were not receiving replacement therapy with L-thyroxine. Therefore, these changes could not be explained by T j induced suppression of thyroid gland. The decrease i n serum l e v e l s of T4 was not influenced by hGH therapy. I n conclusion. h(31 causes an increase i n the b a s a l l e v e l of serum Tj and an augmentation of T j l e v e l s following a loading dose of Tg; mechanisms f o r these changes a r e not known. The decrease i n serum l e v e l s of Tq following a T j load, although not a l t e r e d by hGH. is of s p e c i a l i n t e r e s t . This e f f e c t seems t o be due t o changes i n e x t r a t h y r o i d a l metabolism of Tq. Although small f o l l i c u l a r ovarian c y s t s a r e common i n asymptomatic prepubertal g i r l s , l a r g e r ones may be associated with sexua l precocity which can regress a f t e r cyst r e m v a l . W e report 1 pat i e n t with recurrent functional ovarian c y s t s and another who had a presumptive s i n g l e episode of cyst formation t h a t regressed spontaneously. P a t i e n t 1 developed b r e a s t s a t 3 years and vaginal bleeding a t 4-10112. Plasma e s t r a d i o l (E2) was 180 pg/ml and LRF response was prepubertal (LH 0.4-0.8 n g / d LER-960). E2 l e v e l s f e l l within 6 weeks t o <10 pglml and remained low u n t i l 5-3/12 when bleeding recurred with E2 796 pg/ml. A 4x3 cm ovarian foll i c u l a r cyst with p a r t i a l l u t e i n i z a t i o n was removed from the l e f t ovary. Cyst f l u i d contained 70.300 pglml E2; 21.600 pglml El. Post-op the LRF t e s t remained prepubertal when E2 was <10 pg/ml. A t 5-5/12 E2 was 500 pglml and vaginal bleeding recurred. Treatment was begun with medroxyprogesterone a c e t a t e ; during 20 months of therapy E2 has gradually f a l l e n t o <10 pglml and gonadotropin response t o LRF remains prepubertal (LH 0.7-1.8 ng/ml). P a t i e n t 2 presented a t 3-11/12 with b r e a s t development and E2 279 pglml. E2 f e l l t o <10 p g / d within 1 month and remained low f o r 2 years. A t 6 years (BA 7-10112) E2 was 1 3 pg/ml and the LRF t e s t was pubert a l . I n sum 1) Markedly elevated E2 l e v e l s can occur i n functiona l ovarian c y s t s a s well a s tumors. 2) Sporadic ovarian c y s t formation may underlie some instances of premature thelarche or a r r e s t e d sexual precocity. Single weekly i n j e c t i o n s of 2.5-hGH have been given f o r g r e a t e r than one year t o 15 children with hypopituitarism who had been growing 2.8cm/yr(+1.2SD).
REPLACEMENT THERAPY WITH HUMAN GROWTH HORMONE (hGH
Six were receiving T, two of whom a l s o received low dose C o r t i s o l (C). One C-treated and one who developed hypothyroidism (HT) f a i l e d t o respond t o hGH the f i r s t year. The other 1 3 p t s grew 8.2cm(i1.5) the 1st y r and 4 of them grew 7.2cm(+1.9) during y r 2 on 2.5mgIwk. The two who f a i l e d t o respond t h e 1st y r d i d respond t o 2.5mg Zxlwk but T therapy i n one and stopping C i n t h e other with only 2.5mgIwk produced greater growth (3.5 -8.2 -11.8cmlyr). Three o t h e r s had 2nd y r f a i l u r e due t o acquired HT (2cmlyrf.2) with marked improvement on T (9f.2). Two without c r y p t i c HT responded poorly t o 2.5/wk a f t e r 1 y r and b e t t e r t o 2 . 5~ twice weekly. Twenty-two f u l l treatment y r s a t 2.5mglwk without HT o r C suppreasion included 1 3 1 s t y r , 4 2nd y r and 5 3rd y r periods with average growth 8.6cm/yr(f1.6).
This exceeds 1st y r r a t e s f o r t h e U.S. Collaborative Study (7.Ocmlyr) using 2mg 3xIwk o r the Tanner s e r i e s with 4x our dose (7.3cmIyr the 1st y rp<.025). Four of 9 without HT a t t h e o u t s e t developed r e s i stance t o hGH from acquired HT. Single weekly i n j e c t i o n s of 2.5mg hGH a r e adequate f o r growth i n most cases and should be accompanied by routine T therapy and minimal C replacement. 
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